0001077183-26-000023
SEC filingNeoGenomics delivered stronger financial performance in Q1 FY2026, with revenue up 11.1% and operating loss narrowing by 34.4% year-over-year — driven by clinical volume growth and lower non-recurring legal and transaction costs, partially offset by higher supplies and compensation expenses.
Revenue increased 11.1% to $186.7 million in Q1 FY2026, driven by underlying clinical demand — including test volume expansion, a deliberate shift toward higher-value molecular and MRD assays, and successful execution of strategic reimbursement initiatives. The April 2025 acquisition of Pathline LLC contributed meaningfully to this growth, extending NeoGenomics’ geographic reach and service capabilities in the Northeast U.S. This clinical strength was partially counterbalanced by lower non-clinical revenue from pharmaceutical development services, attributed to macro-level softness in clinical trial enrollment and broader industry trends — not internal execution issues.
NeoGenomics continues to finance operations through cash generated from operations, public and private sales of debt and equity securities, and bank debt borrowings. Operating needs include funding working capital, capital expenditures, research and development efforts, and potential strategic acquisitions and investments — all consistent with the company’s long-term growth objectives and current stage of operational maturity.